ABCZY:OTC-Abcam plc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 18.48

Change

-0.36 (-1.91)%

Market Cap

USD 4.35B

Volume

0.10M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Company Website : http://www.abcam.com

Address : Discovery Drive, Cambridge, United Kingdom, CB2 0AX

Employees : 1,492

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 0.62

52 Week High : 20.87

52 Week Low : 11.22

200 Day Moving Average : 17.39

50 Day Moving Average : 18.27

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+1.97 (+3.03%)

 USD148.61B 24.39 2.70
CSLLY CSL Limited

-2.88 (-2.45%)

 USD107.08B 46.54 27.25
CMXHF CSL Limited

+0.99 (+0.43%)

 USD106.37B 45.96 27.25
GNMSF Genmab A/S

+8.80 (+2.48%)

 USD23.02B 26.75 2.65
UCBJY UCB SA

+0.28 (+0.51%)

 USD20.65B 23.17 17.71
UCBJF UCB SA

N/A

 USD20.49B 23.96 17.71
SBHMY Sino Biopharmaceutical Limited

N/A

 USD18.85B 52.10 3.18
SBMFF Sino Biopharmaceutical Limited

+0.08 (+8.33%)

 USD18.85B 47.84 3.18
PPTDF PeptiDream Inc

N/A

 USD5.81B 260.99 1.61
ABCZF Abcam plc

N/A

 USD4.25B 239.99 106.86

ETFs Containing ABCZY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.54% 43% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.54% 42% F 54% F
Trailing 12 Months  
Capital Gain 10.72% 51% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.72% 50% F 59% F
Trailing 5 Years  
Capital Gain 107.64% 78% C+ 77% C+
Dividend Return 5.32% 20% F 24% F
Total Return 112.96% 78% C+ 76% C
Average Annual (5 Year Horizon)  
Capital Gain 17.86% N/A N/A 69% D+
Dividend Return 0.88% N/A N/A 38% F
Total Return 18.74% N/A N/A 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 23.78% N/A N/A 66% D
Risk Adjusted Return 78.81% N/A N/A 95% A
Market Capitalization 4.35B 96% A 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 236.08 11% F 3% F
Price/Book Ratio 6.38 49% F 20% F
Price / Cash Flow Ratio 69.05 3% F 3% F
EV/EBITDA 106.86 7% F 4% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 2.94% 60% D- 48% F
Return on Assets 4.42% 91% A- 83% B
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.62 55% F 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.